 |
The vaccine is currently authorized for ages 12 and older. Pfizer is now conducting clinical trials in children ages 6 months to 11 years, and the data should be ready to submit to the FDA in the next few months.
“We are planning for emergency use authorization submission for the older age group [ages 5-11] in September or October of this year, and the younger group to follow soon thereafter,” Alejandra Gurtman, MD, Pfizer’s vice president of vaccine clinical research and development, said during a virtual symposium on Wednesday.
Head over to WebMD to read the full story.
